清肿瘤预处理方案用于自体造血干细胞移植治疗难治/复发非霍奇金淋巴瘤的临床观察  

Clinical Efficacy of Autologous Hematopoietic Stem Cell Transplantation Using Tumor-ablative Conditioning Regimen for Patients with Refractory/Relapsed Non-Hodgkin's Lymphoma

作　　者：杨雪良[1] 吴亚妹[1] 曹永彬[1] 李晓红[1] 徐丽昕[1] 刘周阳[1] 刘蓓[1] 闫蓓[1] 李松威[1] 达万明[2] 吴晓雄[1] 

机构地区：[1]解放军总医院第一附属医院血液科,北京100048 [2]解放军总医院血液科,北京100853

出　　处：《中国实验血液学杂志》2016年第6期1743-1747,共5页Journal of Experimental Hematology

摘　　要：目的:观察清肿瘤预处理方案的自体造血干细胞移植治疗难治/复发非霍奇金淋巴瘤的安全性和有效性。方法:回顾性分析2013年1月至2015年7月接受本预处理方案的16例难治/复发非霍奇金淋巴瘤病例临床资料,评估预处理相关毒性、植入情况、感染发生情况及复发率和生存率。结果:未发现预处理相关脏器衰竭及死亡事件;1例患者植入不良,植入率为93.7%;严重感染发生率为31.2%。中位随访20.5(1-30)个月,3例死亡,其中2例为复发相关死亡。2年总生存率为80.2%,2年无病生存率为74.5%,2年复发率为20.6%。结论:清肿瘤化疗方案联合减低剂量预处理方案的自体造血干细胞移植治疗难治/复发非霍奇金淋巴瘤初步结果为安全有效,对降低移植后复发具有一定作用。Objective：To investigate the safety and effectiveness of autologous hematopoietic stem cell transplantation（auto-HSCT） using tumor-ablative conditioning regiment for patients with refractory/relapsed nonHodgkin＇s lymphoma.Methods：The clinical data of 16 patients with refractory/relapsed non-Hodgkin＇s lymphoma received above-mentioned therapeutic regimen from January 2013 to July 2015 was analyzed retrospectively,and conditioning-related toxicity,engraftment,infection,relapse and survival rate were evaluated.Results：No conditioning-related organs＇ failure and mortality were found.Only 1 patient had not been engrafted,and the engraftment rate was 93.7%.The incidence of serious infection was 31.2%.The median follow-up was 20.5（1- 30） months,and3 patients died,out of them 2 patients died of relapse.Two year overall survival（OS）,disease-free survival（DFS）and relapse rates were 80.2%,74.5%and 20.6%respectively.Conclusion：Auto-HSCT using tumor- ablative conditioning regimen is safe and effective for patients with refractory/relapsed non-Hodgkin＇s lymphoma,and it possess a certain effect for reducing disease relapse after transplantation.

关 键 词：移植预处理 自体造血干细胞移植 难治/复发非霍奇金淋巴瘤 

分 类 号：R733.1[医药卫生—肿瘤]